228 related articles for article (PubMed ID: 25704763)
1. A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.
Martorelli D; Muraro E; Mastorci K; Dal Col J; Faè DA; Furlan C; Giagulli C; Caccuri F; Rusnati M; Fiorentini S; Carbone A; Caruso A; Dolcetti R
Int J Cancer; 2015 Sep; 137(6):1374-85. PubMed ID: 25704763
[TBL] [Abstract][Full Text] [Related]
2. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
[TBL] [Abstract][Full Text] [Related]
3. Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus.
Martin HJ; Lee JM; Walls D; Hayward SD
J Virol; 2007 Sep; 81(18):9748-58. PubMed ID: 17609264
[TBL] [Abstract][Full Text] [Related]
4. Transactivation of CCL20 gene by Epstein-Barr virus latent membrane protein 1.
Okudaira T; Yamamoto K; Kawakami H; Uchihara JN; Tomita M; Masuda M; Matsuda T; Sairenji T; Iha H; Jeang KT; Matsuyama T; Takasu N; Mori N
Br J Haematol; 2006 Feb; 132(3):293-302. PubMed ID: 16409294
[TBL] [Abstract][Full Text] [Related]
5. Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth.
Caccuri F; Giagulli C; Reichelt J; Martorelli D; Marsico S; Bugatti A; Barone I; Rusnati M; Guzman CA; Dolcetti R; Caruso A
J Virol; 2014 May; 88(10):5706-17. PubMed ID: 24623414
[TBL] [Abstract][Full Text] [Related]
6. Latent membrane protein 1 of Epstein-Barr virus plays an important role in the serum starvation resistance of Epstein-Barr virus-immortalized B lymphocytes.
Park CH; Kim HR; Kim J; Jang SH; Lee KY; Chung GH; Jang YS
J Cell Biochem; 2004 Mar; 91(4):777-85. PubMed ID: 14991769
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus infection and associated products (LMP, EBNA2, vIL-10) in nodal non-Hodgkin's lymphoma of human immunodeficiency virus-negative Japanese.
Ohshima K; Suzumiya J; Tasiro K; Mukai Y; Tanaka T; Kato A; Kikuchi M
Am J Hematol; 1996 May; 52(1):21-8. PubMed ID: 8638607
[TBL] [Abstract][Full Text] [Related]
9. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.
Terrin L; Dolcetti R; Corradini I; Indraccolo S; Dal Col J; Bertorelle R; Bonaldi L; Esposito G; De Rossi A
Int J Cancer; 2007 Aug; 121(3):576-87. PubMed ID: 17417773
[TBL] [Abstract][Full Text] [Related]
10. Epstein Barr virus genotypes and LMP-1 variants in HIV-infected patients.
Correa RM; Fellner MD; Durand K; Redini L; Alonio V; Yampolsky C; Colobraro A; Sevlever G; Teyssié A; Benetucci J; Picconi MA
J Med Virol; 2007 Apr; 79(4):401-7. PubMed ID: 17311329
[TBL] [Abstract][Full Text] [Related]
11. Induction of latent membrane protein expression in in vitro Epstein-Barr virus-infected leukaemic B lymphocytes by interleukin 4 and antibodies to CD40.
Crawford DH; Thomas JA; Gregory CD; Catovsky D; Chaggar K
Leukemia; 1995 May; 9(5):747-53. PubMed ID: 7539512
[TBL] [Abstract][Full Text] [Related]
12. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
[TBL] [Abstract][Full Text] [Related]
13. Expression of latent membrane proteins in Epstein‑Barr virus-transformed lymphocytes in vitro.
Tang Y; Luo C; Cheng A; Lu S; Xu J; Fu T; Gan R
Mol Med Rep; 2014 Aug; 10(2):1117-21. PubMed ID: 24919846
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.
Rasul AE; Nagy N; Sohlberg E; Ádori M; Claesson HE; Klein G; Klein E
J Immunol Methods; 2012 Nov; 385(1-2):60-70. PubMed ID: 22921685
[TBL] [Abstract][Full Text] [Related]
15. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents.
Kenney JL; Guinness ME; Reiss M; Lacy J
Int J Cancer; 2001 Jan; 91(1):89-98. PubMed ID: 11149426
[TBL] [Abstract][Full Text] [Related]
16. Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity.
Rainio EM; Ahlfors H; Carter KL; Ruuska M; Matikainen S; Kieff E; Koskinen PJ
Virology; 2005 Mar; 333(2):201-6. PubMed ID: 15721354
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.
Ren Q; Sato H; Murono S; Furukawa M; Yoshizaki T
Laryngoscope; 2004 May; 114(5):855-9. PubMed ID: 15126743
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
[TBL] [Abstract][Full Text] [Related]
20. Survivin messenger RNA levels in Epstein-Barr virus-positive patients with leukemic low-grade B-cell lymphomas expressing the latent membrane protein 1: evidence of apoptotic function?
Diamantopoulos PT; Polonyfi K; Sofotasiou M; Mantzourani M; Galanopoulos A; Spanakis N; Papadopoulou V; Kalala F; Iliakis T; Zareifi DS; Kodandreopoulou E; Vassilakopoulos T; Angelopoulou M; Siakantaris M; Terpos E; Variami E; Kollia P; Vaiopoulos G; Pangalis G; Viniou NA
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):56-60. PubMed ID: 24262330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
